Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Rezafungin (Rezzayo) vs Triptorelin (Trelstar)
An educational, source-based comparison of Rezafungin (Rezzayo) and Triptorelin (Trelstar) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
Decapeptide GnRH agonist that initially stimulates then desensitizes pituitary GnRH receptors, suppressing LH, FSH, and downstream gonadal steroid production after the initial flare.
- Advanced prostate cancer
- Central precocious puberty (international)
- Endometriosis (international)
- • FDA-approved.
- • Initial testosterone flare; consider antiandrogen pretreatment.
- • Hot flashes, bone density loss with chronic use.
Rezafungin (Rezzayo) vs Triptorelin (Trelstar) — Key differences
- Class: Rezafungin (Rezzayo) is classified as Echinocandin · Antifungal, while Triptorelin (Trelstar) is GnRH Agonist · Oncology.
- Primary research focus: Rezafungin (Rezzayo) — candidemia; Triptorelin (Trelstar) — advanced prostate cancer.
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Oncology.